Women with ductal carcinoma in situ (DCIS) who exhibit an overexpression of the protein HER2/neu have a six-fold increase in risk of invasive breast cancer, according to a new study. The results may help clinicians distinguish between DCIS that requires minimal treatment and DCIS that should be treated more aggressively.